UNSPSC 51371910: Methadone hydrochloride

This classification denotes a synthetic opioid, opiate substitution treatment, analgesics, and antitussive agent with the molecular formula C21H27NO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 229809935B, chemically known as 6-dimethylamino-4,4-diphenyl-heptan-3-one but more generally known as methadone hydrochloride, which bears US NIH Compound Identifier 4095. European Medicines Agency schedules Methadone hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03203MIG.

UNSPSC 51371910 Methadone hydrochloride is a Commodity code representing pharmaceutical products purchased by state and local health agencies, but recent state and local solicitations tagged under this code show minimal direct demand for methadone itself. Instead, the tagged opportunities reflect broader pharmaceutical procurement across generic multi-source drugs, naloxone, and pharmacy benefit program sourcing — activity that spans state health and human services departments, county health systems, and cooperative purchasing alliances. The actual purchasing pattern under this code at the state and local level focuses on establishing supply agreements with manufacturers and wholesalers for a range of pharmaceutical products rather than single-drug procurement, with an emphasis on compliance with Good Manufacturing Practices, Drug Supply Chain Security Act certification, and authorized wholesaler distribution channels.

The most recent activity concentrates in Texas, Florida, and Minnesota, with a cooperative purchasing vehicle extending to Oregon. Representative solicitations include the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP for generic multi-source pharmaceuticals and OTC products (posted January 20, 2026, due March 26, 2026), which establishes multi-award contracts across participating state and local government facilities and requires manufacturers to supply through AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson with cGMP and DSCSA compliance; Seminole County, Florida's IFB for naloxone and drug deactivation systems (posted June 30, 2026, due July 26, 2023) for annual procurement of 1,900 naloxone units and 800 safe drug deactivation systems with quarterly delivery to county health facilities; and the Texas Health and Human Services Commission's RFI for direct-to-manufacturer prescription programs (posted April 3, 2026), which seeks vendor capabilities to establish direct relationships between the state's pharmacy benefit program and manufacturers outside traditional pharmacy benefit manager arrangements. These opportunities target manufacturers and distributors capable of multi-jurisdictional supply, not single-product commodity vendors.